Literature DB >> 10168894

Cytomegalovirus optic neuritis.

A M Mansour1.   

Abstract

Cytomegalovirus (CMV) optic neuritis is a rapidly blinding disease. Untreated eyes have a final visual acuity of no light perception. Treated eyes maintain visual acuity of approximately 20/100. Relapse occurs often in subjects maintained on single-dose ganciclovir and is controlled by double-dose ganciclovir. Central visual field testing is indicated to detect indolent cases of optic neuritis, because relapse can be silent with stable visual acuity and fundus appearance. Survival of patients with CMV optic neuritis is comparable to that of a matched group having CMV retinitis alone. Early recognition and therapy of CMV papillitis protect against irreversible visual loss. CMV papillitis does not carry a worse prognosis for survival than CMV retinitis alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10168894     DOI: 10.1097/00055735-199706000-00010

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

1.  Cytomegalovirus and eye.

Authors:  R Agrawal
Journal:  Eye (Lond)       Date:  2012-05-25       Impact factor: 3.775

Review 2.  Infectious optic neuropathies: a clinical update.

Authors:  Rim Kahloun; Nesrine Abroug; Imen Ksiaa; Anis Mahmoud; Hatem Zeghidi; Sonia Zaouali; Moncef Khairallah
Journal:  Eye Brain       Date:  2015-09-28

Review 3.  Atypical optic neuritis: An overview.

Authors:  Prathama Sarkar; Amit Mehtani; H C Gandhi; Vinita Dubey; Parag Maroti Tembhurde; Mohit Kumar Gupta
Journal:  Indian J Ophthalmol       Date:  2021-01       Impact factor: 1.848

4.  Cytomegalovirus optic neuropathy in a young immunocompetent patient.

Authors:  Diana Melancia; Andreia Fernandes; Manuel Manita; Inês Menezes Cordeiro
Journal:  J Neurovirol       Date:  2021-03-15       Impact factor: 2.643

5.  Combined Cytomegalovirus and Herpes Simplex Virus-related Neuroretinitis in an Immunocompetent Patient.

Authors:  Suntaree Thitiwichienlert; Supinda Leeamornsiri
Journal:  Korean J Ophthalmol       Date:  2019-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.